{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T15:01:07Z","timestamp":1783004467695,"version":"3.54.5"},"reference-count":30,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T00:00:00Z","timestamp":1627689600000},"content-version":"unspecified","delay-in-days":30,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["U01AG029824"],"award-info":[{"award-number":["U01AG029824"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute at the National Institutes of Health","doi-asserted-by":"crossref","award":["1127060"],"award-info":[{"award-number":["1127060"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute at the National Institutes of Health","doi-asserted-by":"crossref","award":["334047"],"award-info":[{"award-number":["334047"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Heart Foundation Future Leader Fellowship","award":["102604"],"award-info":[{"award-number":["102604"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Open Heart"],"accepted":{"date-parts":[[2021,7,13]]},"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      Genetic variants that disrupt the function of the\n                      <jats:italic>PCSK9<\/jats:italic>\n                      (proprotein convertase subtilisin kexin type 9) and\n                      <jats:italic>APOB<\/jats:italic>\n                      (apolipoprotein B)genes result in lower serum low-density lipoprotein cholesterol (LDL-C) levels and subsequently confer protection against coronary heart disease (CHD). The objective of this study was to measure the prevalence and selective advantage of such variants among healthy older individuals without a history of CHD.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We performed targeted sequencing of the\n                      <jats:italic>PCSK9<\/jats:italic>\n                      and\n                      <jats:italic>APOB<\/jats:italic>\n                      genes in 13\u2009131 healthy individuals without CHD aged 70 years or older enrolled into the ASPirin in Reducing Events in the Elderly trial. We detected variants in the\n                      <jats:italic>PCSK9<\/jats:italic>\n                      and\n                      <jats:italic>APOB<\/jats:italic>\n                      genes with predicted loss-of-function. We associated variant carrier status with serum LDL-C and total cholesterol (TC) levels at the time of study enrolment, adjusting for statin use.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We detected 22 different rare\n                      <jats:italic>PCSK9\/APOB<\/jats:italic>\n                      candidate variants with putative lipid-lowering effect, carried by 104 participants (carrier rate 1 in 126). Serum LDL-C and TC concentrations for rare PCSK9\/APOB variant carriers were consistently lower than non-carriers. Rare variant carrier status was associated with 19.4\u2009mg\/dL (14.6%) lower LDL-C, compared with non-carriers (p\u22640.001, adjusted for statin use). Statin prescriptions were less prevalent in rare variant carriers (16%) than non-carriers (35%). The more common\n                      <jats:italic>PCSK9<\/jats:italic>\n                      R46L variant (rs11591147-T) was associated with 15.5\u2009mg\/dL (11.8%) lower LDL-C in heterozygotes, and 25.2\u2009mg\/dL (19.2%) lower LDL-C in homozygotes (both p\u22640.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Lipid-lowering genetic variants are carried by healthy older individuals and contribute to CHD-free survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01038583\">NCT01038583<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/openhrt-2021-001710","type":"journal-article","created":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T12:29:33Z","timestamp":1627907373000},"page":"e001710","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Protective lipid-lowering variants in healthy older individuals without coronary heart disease"],"prefix":"10.1136","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct01038583","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0902-6798","authenticated-orcid":false,"given":"Paul","family":"Lacaze","sequence":"first","affiliation":[{"name":"Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moeen","family":"Riaz","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Sebra","sequence":"additional","affiliation":[{"name":"Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda J","family":"Hooper","sequence":"additional","affiliation":[{"name":"School of Medicine, Faculty of Medicine and Health Sciences, The University of Western Australia, Perth, Western Australia, Australia"},{"name":"Department of Clinical Biochemistry, PathWest Laboratory Medicine WA, Royal Perth Hospital and Fiona Stanley Hospital Network, Royal Perth Hospital, Perth, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9700-6948","authenticated-orcid":false,"given":"Jing","family":"Pang","sequence":"additional","affiliation":[{"name":"School of Medicine, Faculty of Medicine and Health Sciences, The University of Western Australia, Perth, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Tiller","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galina","family":"Polekhina","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Tonkin","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Reid","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia"},{"name":"School of Public Health, Curtin University, Perth, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Zoungas","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M","family":"Murray","sequence":"additional","affiliation":[{"name":"Berman Center for Outcomes and Clinical Research, Hennepin Healthcare Research Institute, Hennepin Healthcare, Minneapolis, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Nicholls","sequence":"additional","affiliation":[{"name":"Monash Cardiovascular Research Centre, Monash University and MonashHeart, Monash Health, Clayton, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Watts","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, PathWest Laboratory Medicine WA, Royal Perth Hospital and Fiona Stanley Hospital Network, Royal Perth Hospital, Perth, Western Australia, Australia"},{"name":"Lipid Disorders Clinic, Department of Cardiology, Royal Perth Hospital, Perth, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Schadt","sequence":"additional","affiliation":[{"name":"Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J","family":"McNeil","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,8,2]]},"reference":[{"key":"2025081709533977000_8.2.e001710.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054013"},{"key":"2025081709533977000_8.2.e001710.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510926"},{"key":"2025081709533977000_8.2.e001710.3","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.118.002376","article-title":"Rare protein-truncating variants in ApoB, lower low-density lipoprotein cholesterol, and protection against coronary heart disease","volume":"12","author":"Peloso","year":"2019","journal-title":"Circ Genom Precis Med"},{"key":"2025081709533977000_8.2.e001710.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1604304"},{"key":"2025081709533977000_8.2.e001710.5","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.117.311145"},{"key":"2025081709533977000_8.2.e001710.6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.20045"},{"key":"2025081709533977000_8.2.e001710.7","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/564940","article-title":"Meta-analysis of low density lipoprotein receptor (LDLR) rs2228671 polymorphism and coronary heart disease","volume":"2014","author":"Ye","year":"2014","journal-title":"Biomed Res Int"},{"key":"2025081709533977000_8.2.e001710.8","first-page":"11","article-title":"Common and rare gene variants affecting plasma LDL cholesterol","volume":"29","author":"Burnett","year":"2008","journal-title":"Clin Biochem Rev"},{"key":"2025081709533977000_8.2.e001710.9","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.atherosclerosis.2016.04.010","article-title":"Identification of novel ApoB mutations by targeted next-generation sequencing for the molecular diagnosis of familial hypobetalipoproteinemia","volume":"250","author":"Rimbert","year":"2016","journal-title":"Atherosclerosis"},{"key":"2025081709533977000_8.2.e001710.10","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/MOL.0000000000000386","article-title":"Complexity of mechanisms among human proprotein convertase subtilisin-kexin type 9 variants","volume":"28","author":"Dron","year":"2017","journal-title":"Curr Opin Lipidol"},{"key":"2025081709533977000_8.2.e001710.11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.290.15.2030"},{"key":"2025081709533977000_8.2.e001710.12","doi-asserted-by":"publisher","DOI":"10.1097\/MOL.0000000000000072"},{"key":"2025081709533977000_8.2.e001710.13","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/ehjcvp\/pvx031","article-title":"New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk","volume":"4","author":"Graham","year":"2018","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2025081709533977000_8.2.e001710.14","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1093\/gerona\/glw342","article-title":"Baseline characteristics of participants in the ASPREE (aspirin in reducing events in the elderly) study","volume":"72","author":"McNeil","year":"2017","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"2025081709533977000_8.2.e001710.15","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1805819","article-title":"Effect of aspirin on cardiovascular events and bleeding in the healthy elderly","volume":"379","author":"McNeil","year":"2018","journal-title":"N Engl J Med"},{"key":"2025081709533977000_8.2.e001710.16","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1056\/NEJMoa1800722","article-title":"Effect of aspirin on disability-free survival in the healthy elderly","volume":"379","author":"McNeil","year":"2018","journal-title":"N Engl J Med"},{"key":"2025081709533977000_8.2.e001710.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803955"},{"key":"2025081709533977000_8.2.e001710.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2013.09.014"},{"key":"2025081709533977000_8.2.e001710.19","doi-asserted-by":"crossref","first-page":"105","DOI":"10.5694\/j.1326-5377.2008.tb01932.x","article-title":"Feasibility of conducting a primary prevention trial of low-dose aspirin for major adverse cardiovascular events in older people in Australia: results from the aspirin in reducing events in the elderly (ASPREE) pilot study","volume":"189","author":"Nelson","year":"2008","journal-title":"Med J Aust"},{"key":"2025081709533977000_8.2.e001710.20","doi-asserted-by":"publisher","DOI":"10.5694\/mja2.12060"},{"key":"2025081709533977000_8.2.e001710.21","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.120.002938","article-title":"Familial hypercholesterolemia in a healthy elderly population","volume":"13","author":"Lacaze","year":"2020","journal-title":"Circ Genom Precis Med"},{"key":"2025081709533977000_8.2.e001710.22","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1038\/s41436-020-0881-7","article-title":"Medically actionable pathogenic variants in a population of 13,131 healthy elderly individuals","volume":"22","author":"Lacaze","year":"2020","journal-title":"Genet Med"},{"key":"2025081709533977000_8.2.e001710.23","doi-asserted-by":"publisher","DOI":"10.1038\/nature19057"},{"key":"2025081709533977000_8.2.e001710.24","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-20281-9","article-title":"New sequencing technologies help revealing unexpected mutations in autosomal dominant hypercholesterolemia","volume":"8","author":"Elbitar","year":"2018","journal-title":"Sci Rep"},{"key":"2025081709533977000_8.2.e001710.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.02.044"},{"key":"2025081709533977000_8.2.e001710.26","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2015.30"},{"key":"2025081709533977000_8.2.e001710.27","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60367-5"},{"key":"2025081709533977000_8.2.e001710.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.09.017"},{"key":"2025081709533977000_8.2.e001710.29","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/imj.13384","article-title":"The genomic potential of the aspirin in reducing events in the elderly and statins in reducing events in the elderly studies","volume":"47","author":"Lacaze","year":"2017","journal-title":"Intern Med J"},{"key":"2025081709533977000_8.2.e001710.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2014.06.009"}],"container-title":["Open Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/openhrt-2021-001710","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,17]],"date-time":"2025-08-17T16:53:50Z","timestamp":1755449630000},"score":1,"resource":{"primary":{"URL":"https:\/\/openheart.bmj.com\/lookup\/doi\/10.1136\/openhrt-2021-001710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,8,2]]},"published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.1136\/openhrt-2021-001710"],"URL":"https:\/\/doi.org\/10.1136\/openhrt-2021-001710","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.02.16.21251811","asserted-by":"object"}]},"ISSN":["2053-3624"],"issn-type":[{"value":"2053-3624","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7]]}}}